相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)
Mario Campone et al.
EUROPEAN JOURNAL OF CANCER (2021)
Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling
Farnaz Khodabakhsh et al.
CANCER CELL INTERNATIONAL (2021)
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
Apostolia-Maria Tsimberidou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
Marta Sanz-Alvarez et al.
CANCERS (2021)
Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy
Huma Khan et al.
PHARMACEUTICS (2021)
WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer
Andrea Sand et al.
CANCER LETTERS (2020)
Role of STAT3 signaling pathway in breast cancer
Jia-hui Ma et al.
CELL COMMUNICATION AND SIGNALING (2020)
An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
Alexandre Perrier et al.
PLOS ONE (2020)
Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
Hiroki Irie et al.
CANCER SCIENCE (2020)
Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells
Min Jung Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A. Jo Chien et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab
Mengjun Shu et al.
NANOTECHNOLOGY (2020)
Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
Miguel A. Ortega et al.
JOURNAL OF ONCOLOGY (2020)
Synthesis, conformational analysis and in vivo assays of an anti-cancer vaccine that features an unnatural antigen based on an sp2-iminosugar fragment
Iris A. Bermejo et al.
CHEMICAL SCIENCE (2020)
Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1
Masashi Namba et al.
CANCER LETTERS (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer
Satomi Watanabe et al.
CANCER MEDICINE (2019)
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Ru Zhou et al.
FRONTIERS IN IMMUNOLOGY (2019)
Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance
Florian Reinhardt et al.
CANCERS (2019)
Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice
Jennifer M. Curry et al.
PLOS ONE (2019)
Crosstalk between MUC1 oncoprotein and ER, PR, and HER2 receptors in breast cancer cells
N. Jalili et al.
EUROPEAN JOURNAL OF CANCER (2018)
Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells
Varun Sasidharan Nair et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
The Multifaceted Role of STAT3 in Mammary Gland Involution and Breast Cancer
Katherine Hughes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER
Shima Moradi-Kalbolandi et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2018)
Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer
Lina Liu et al.
MOLECULAR THERAPY (2018)
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Masayuki Hiraki et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Takahiro Maeda et al.
CANCER RESEARCH (2018)
Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations
Fagner Santos do Carmo et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin et al.
EUROPEAN JOURNAL OF CANCER (2017)
MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer
Parnaz Merikhian et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner
Wei Jin et al.
CELL DEATH & DISEASE (2017)
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
Martine J. Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
Komal Jhaveri et al.
BREAST CANCER RESEARCH (2017)
Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients
Carlo Fremd et al.
ONCOIMMUNOLOGY (2016)
Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus
Priya Pai et al.
CARCINOGENESIS (2016)
Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
Masanori Hasegawa et al.
ONCOTARGET (2016)
MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors
Masayuki Hiraki et al.
SCIENTIFIC REPORTS (2016)
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick et al.
BMC MEDICINE (2015)
Multifunctional receptor-targeting antibodies for cancer therapy
Yanni Zhu et al.
LANCET ONCOLOGY (2015)
Mechanisms of action of therapeutic antibodies for cancer
J. M. Redman et al.
MOLECULAR IMMUNOLOGY (2015)
The Path to Cancer - Three Strikes and You're Out
Bert Vogelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer
Yingbo Shao et al.
PLOS ONE (2015)
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Mark A. Feitelson et al.
SEMINARS IN CANCER BIOLOGY (2015)
Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab
Fan Zhang et al.
ONCOIMMUNOLOGY (2015)
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER plus breast cancer
Jennifer R. Bean et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer
L. M. Dillon et al.
ONCOGENE (2015)
Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target
Deepak Raina et al.
PLOS ONE (2015)
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Kodappully Sivaraman Siveen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
Pernelle Lavaud et al.
BMC MEDICINE (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/β-catenin pathway and interaction with SNAIL promoter
Viviane Gnemmi et al.
CANCER LETTERS (2014)
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
Eva Maria Ciruelos Gil
CANCER TREATMENT REVIEWS (2014)
A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
Komal Jhaveri et al.
CLINICAL BREAST CANCER (2014)
Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines
Elham Mohit et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
An Investigation of the Effects of the Core Protein Telomerase Reverse Transcriptase on Wnt Signaling in Breast Cancer Cells
Imke Listerman et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
D. Raina et al.
ONCOGENE (2014)
Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells
Maroof Alam et al.
ONCOTARGET (2014)
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression
Guangchao Li et al.
ONCOTARGET (2014)
MUC1 regulates cyclin D1 gene expression through p120 catenin and β-catenin
X. Liu et al.
ONCOGENESIS (2014)
Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells
Zuowei Zhao et al.
BREAST CANCER RESEARCH (2014)
Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium
Gabriella Honeth et al.
BREAST CANCER RESEARCH (2014)
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer
B. V. Sinn et al.
ANNALS OF ONCOLOGY (2013)
Effect of MUC1 siRNA on Drug Resistance of Gastric Cancer Cells to Trastuzumab
Min Deng et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Molecular aspects of cancer cell resistance to chemotherapy
Magali Rebucci et al.
BIOCHEMICAL PHARMACOLOGY (2013)
The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression
Junli Deng et al.
CANCER AND METASTASIS REVIEWS (2013)
Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells
Yasumitsu Uchida et al.
CANCER BIOLOGY & THERAPY (2013)
Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2-Overexpressing Metastatic Breast Cancer
Yuan Huang et al.
CURRENT DRUG TARGETS (2013)
MUC1-C Oncoprotein Activates ERK→C/EBPβ Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells
Maroof Alam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer
Akriti Kharbanda et al.
MOLECULAR CANCER RESEARCH (2013)
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
D. W. Kufe
ONCOGENE (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Role of STAT3 in Cancer Metastasis and Translational Advances
Mohammad Zahid Kamran et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Crosstalk between NFkB and glucocorticoid signaling: A potential target of breast cancer therapy
Jun Ling et al.
CANCER LETTERS (2012)
Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Qingfei Wang et al.
CANCER RESEARCH (2012)
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
Anna Emde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
The MUC1-C Oncoprotein Binds to the BH3 Domain of the Pro-apoptotic BAX Protein and Blocks BAX Function
Rehan Ahmad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
MUC1 Drives c-Met-Dependent Migration and Scattering
Teresa M. Horm et al.
MOLECULAR CANCER RESEARCH (2012)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+Breast Cancer by Expanding the Cancer Stem Cell Population
Hasan Korkaya et al.
MOLECULAR CELL (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin αvβ5 Depends on Activation of c-Src and Cleavage of MUC1
Steven K. M. Lau et al.
PLOS ONE (2012)
MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells
Hasan Rajabi et al.
PROSTATE (2012)
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
Andrea L. A. Wong et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Nuhad K. Ibrahim et al.
CLINICAL CANCER RESEARCH (2011)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash et al.
CLINICAL CANCER RESEARCH (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells
Deepak Raina et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
NF-kappa B, stem cells and breast cancer: the links get stronger
Kateryna Shostak et al.
BREAST CANCER RESEARCH (2011)
Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.
S. Hurvitz et al.
CANCER RESEARCH (2010)
Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
Xiaoping Huang et al.
CANCER RESEARCH (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer
N. Khodarev et al.
ONCOGENE (2010)
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Shawn P. Fessler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor-κB p65 Transcription Factor
Rehan Ahmad et al.
CANCER RESEARCH (2009)
MUC1-Induced Transcriptional Programs Associated with Tumorigenesis Predict Outcome in Breast and Lung Cancer
Nikolai N. Khodarev et al.
CANCER RESEARCH (2009)
Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
Deepak Raina et al.
CANCER RESEARCH (2009)
How ERK1/2 activation controls cell proliferation and cell death is subcellular localization the answer?
Yohannes Mebratu et al.
CELL CYCLE (2009)
Intracellular MUC1 Peptides Inhibit Cancer Progression
Benjamin G. Bitler et al.
CLINICAL CANCER RESEARCH (2009)
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Bryan T. MacDonald et al.
DEVELOPMENTAL CELL (2009)
MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment
Sean P. Pitroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Mucins in cancer: function, prognosis and therapy
Donald W. Kufe
NATURE REVIEWS CANCER (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
Mark D. Pegram et al.
BREAST CANCER RESEARCH (2009)
MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8
Naoki Agata et al.
CANCER RESEARCH (2008)
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
James L. Gulley et al.
CLINICAL CANCER RESEARCH (2008)
MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling
Rehan Ahmad et al.
NATURE CELL BIOLOGY (2007)
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
Chien-Hsing Lu et al.
CLINICAL CANCER RESEARCH (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Platelet-derived growth factor receptor β-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells
Pankaj K. Singh et al.
CANCER RESEARCH (2007)
MUC1 is a novel regulator of erbB1 receptor trafficking
M. R. Pochampalli et al.
ONCOGENE (2007)
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer
R. L. Dillon et al.
ONCOGENE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Mucin 1 oncoprotein blocks hypoxia-inducible factor 1α activation in a survival response to hypoxia
Li Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
MUCI gene overexpressed in breast cancer:: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expression
Joseph Z. Zaretsky et al.
MOLECULAR CANCER (2006)
Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping
M Doi et al.
CANCER SCIENCE (2006)
MUC1 oncoprotein stabilizes and activates estrogen receptor α
XL Wei et al.
MOLECULAR CELL (2006)
MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90
J Ren et al.
ONCOGENE (2006)
MUC1 oncoprotein blocks glycogen synthase kinase 3β-mediated phosphorylation and degradation of β-catenin
L Huang et al.
CANCER RESEARCH (2005)
Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer
EA Rakha et al.
MODERN PATHOLOGY (2005)
Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response
XL Wei et al.
CANCER CELL (2005)
MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells
P Mukherjee et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents
J Ren et al.
CANCER CELL (2004)
MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation
JA Schroeder et al.
ONCOGENE (2004)
Mucins in cancer: Protection and control of the cell surface
MA Hollingsworth et al.
NATURE REVIEWS CANCER (2004)
MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress
L Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts
D Raina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Inhibition of MUC1 expression by indole-3-carbinol
IJ Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Human DF3/MUC1 carcinoma-associated protein functions as an oncogene
YQ Li et al.
ONCOGENE (2003)
MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion
JA Schroeder et al.
ONCOGENE (2003)
Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha
EL Lagow et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2002)
The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin
YQ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation ill the mouse mammary gland
JA Schroeder et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin
S von Mensdorff-Pouilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
